Homology Medicines, Inc. (FIXX)
Stock Price:
$11.25 USD
0.68 (6.43%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
508.70M |
| Revenue (ttm) |
2.16M |
| Net Income (ttm) |
-124.47M |
| Shares Out |
45.22M |
| EPS (ttm) |
-2.79 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$11.25 |
| Previous Close |
$10.57 |
| Change ($) |
0.68 |
| Change (%) |
6.43% |
| Day's Open |
10.64 |
| Day's Range |
10.59 - 11.29 |
| Day's Volume |
242,997 |
| 52-Week Range |
9.19 - 22.50 |
More Stats
| Market Cap |
508.70M |
| Enterprise Value |
317.39M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
45.22M |
| Float |
29.48M |
| EPS (basic) |
-2.78 |
| EPS (diluted) |
-2.79 |
| FCF / Share |
-2.52 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.43M |
| Short Ratio |
9.58 |
| Short % of Float |
15.02% |
| Beta |
-0.26 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
235.62 |
| PB Ratio |
2.45 |
| Revenue |
2.16M |
| Operating Income |
-129.04M |
| Net Income |
-124.47M |
| Free Cash Flow |
-113.72M |
| Net Cash |
191.31M |
| Net Cash / Share |
4.23 |
| Gross Margin |
-4,063.55% |
| Operating Margin |
-5,976.66% |
| Profit Margin |
-5,764.90% |
| FCF Margin |
-5,267.21% |
| ROA |
-26.91% |
| ROE |
-51.92% |
| ROIC |
-71.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (10)
| Buy |
9 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$29.56*
(162.76% upside)
Low
18.0
Current: $11.25
High
37.0
Target: 29.56
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 1.67 | 5.32 | - | - |
| Revenue Growth | -68.7% | - | - | - |
| Gross Profit | 1.67 | 5.32 | - | - |
| Operating Income | -110 | -59.93 | -29.66 | -10.00 |
| Net Income | -104 | -55.58 | -29.99 | -8.05 |
| Shares Outstanding | 42.12 | 28.55 | 2.48 | 1.90 |
| Earnings Per Share | -2.47 | -1.95 | -12.10 | -4.23 |
| Operating Cash Flow | -91.36 | -42.56 | 6.48 | -8.48 |
| Capital Expenditures | -21.83 | -24.94 | -1.96 | -1.99 |
| Free Cash Flow | -113 | -67.50 | 4.52 | -10.47 |
| Cash & Equivalents | 264 | 217 | 131 | 11.67 |
| Net Cash / Debt | 264 | 217 | 131 | 11.67 |
| Assets | 311 | 259 | 138 | 14.22 |
| Liabilities | 52.06 | 62.74 | 39.22 | 6.72 |
| Book Value | 259 | 196 | -39.45 | -9.89 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Homology Medicines, Inc. |
| Country |
United States |
| Employees |
197 |
| CEO |
Arthur O. Tzianabos |
Stock Information
| Ticker Symbol |
FIXX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FIXX |
Description
Homology Medicines, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.